ERBB2 and gastric cancer: However, pivotal trials including phase III CHECKMATE-649 and ATTRACTION-4 trial demonstrated an efficacy of combination therapy with ICI and chemotherapy in first-line treatment, making this combination therapy an essential treatment option in HER2-negative advanced gastric cancer.